Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast ...

According to WHO, 254 million people globally were estimated to have HBV in 2022, but only approximately 10% had been ...

Results Patients with hepatitis B (HBV) were more likely to develop HCC at a younger age than patients with hepatitis C (HCV) (HBV-26% under age 40, HCV-0% under age 40; p < 0.001), with greater ...

Children and adults vaccinated on the recommended hep B series are afforded lifelong protection against the hepatitis B virus (HBV), a highly infectious virus that attacks the liver. Vaccination ...

In April 2025, Vir Biotechnology Inc. announced a phase 1b/2 platform study framework to evaluate the safety and efficacy of ...

China: A recent retrospective cohort study has highlighted the significant role of pulmonary infections in influencing ...

The company is dedicated to educating patients, providers, and others on new findings in chronic hepatitis B virus (HBV) infection. Chronic HBV infection is the most common viral infection in ...

Spontaneous loss of hepatitis B e antigen (HBeAg) followed by seroconversion to anti-HBe usually coincides with normalization of serum alanine aminotransferase (ALT) levels, reduction in HBV DNA ...

Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...